Skip to main content

ConeCraft Announces Acquisition of G&G Technologies

Written by Customer Service on . Posted in Mergers And Acquisitions.

FORT WORTH, Texas, Oct. 12, 2026 (GLOBE NEWSWIRE) — ConeCraft International, LLC (“ConeCraft”), a global provider of engineered bioprocessing production solutions, is pleased to announce the acquisition of Coventry, Rhode Island-based, G&G Technologies, Inc. (“G&G”). The addition of G&G complements ConeCraft’s current advanced upstream processing solutions through expanded downstream chromatography and filtration capabilities.

Over the past 25 years, G&G has become recognized as an innovation leader in the bioprocessing market, providing complex, custom solutions for the industry’s largest biopharmaceutical manufacturers. With capabilities across upstream, downstream, and ancillary systems, G&G provides support for the entire production cycle, including mixers, bioreactors, chromatography, perfusion systems, tangential flow filtration, micro and nano filtration, lyophilization, lipid nanoparticle mixing, clean-in-place systems, and tube management.

“For more than two decades, G&G has focused on solving the most challenging bioprocessing problems for our customers,” said G&G founder, Genko Genev. “Joining ConeCraft gives our team the scale and expanded capabilities to deliver those solutions across the entire production process.”

The addition of G&G augments ConeCraft’s bioprocessing capabilities, furthering its ability to provide engineered solutions throughout the production process, from cell to vial. With extensive engineering expertise across single-use and multi-use, upstream and downstream, lab and commercial scale, ConeCraft is the partner of choice for leading biopharmaceutical manufacturers seeking to deliver the next generation of biologics effectively and efficiently, across any modality worldwide.

“With the exponential pace of biopharmaceutical development, it’s critical for ConeCraft to stay at the forefront of engineering innovation,” said ConeCraft CEO, Jim Austin. “As a recognized leader in bioprocessing design, G&G is a natural extension of ConeCraft’s existing capabilities. With a shared commitment to production processing improvement, G&G’s downstream experience will allow us to better serve our customers as a complete solutions partner.”

About G&G Technologies

G&G provides customized bioprocess systems backed by deep technical expertise across every stage of biopharmaceutical production. Its engineered solutions help a diverse group of blue-chip biopharmaceutical customers improve efficiency, purity, and yield. Supported by biologics-focused design and process engineers, G&G is well positioned to advance emerging modalities across the rapidly evolving biopharmaceutical landscape. For more information, visit www.ggtechnologies.com.

About ConeCraft International

Headquartered in Fort Worth, Texas, ConeCraft is an engineering partner to leading biopharmaceutical developers with a portfolio of patented solutions designed to improve facility productivity at any scale across both single-use and multi-use systems. The Company’s deep team of engineers drive the development of an expanding suite of innovative and adaptive bioprocess designs across a diverse range of applications. With more than one million liters of production capacity supplied to facilities worldwide, ConeCraft remains at the forefront of biopharmaceutical development. ConeCraft is a portfolio company of Cotton Creek Capital, a lower middle market private equity firm based in Austin, Texas. For more information, visit ConeCraft at www.conecraft.com.

Media Contact:
Andrew Blake
P: (817) 922-9200
ablake@conecraft.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.